4HarrisJE, et al. Adjuvant active specific immunotherapy for stage Ⅱ and Ⅲ colon cancer with an autologous tumor cell caccine:Eastem Coperative Oncology Group Study E5283[J]. J Clin Oncol, 2000,18(1):148~157.
5Vermorken JB,et al.Activ specific immunotherapy for stage Ⅱ and stage Ⅲ human colon cancer:a randomized trial[J].Lancet,1999,353(9150):345-350
2Hung MC, Lau YK. Basic science of her-2/neu: A Review[J]. Semi Oncol, 1999, 26(4 Suppl 12): 51-59.
3Cooley S, Burns LJ, Repka T, et al. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER-2/neu[J]. Exp Hematol, 1999, 27(10): 1533-1541.
4Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development[J]. Immunol Rev, 1999, 170: 85-100.
5Foon KA. Vaccine therapies for epithelial cancers [C]. 2000 by American Society of Clinical Oncology, 730-738.
6Harris JE, Ryan L, Hoover HC, et al. Adjuvant active specific immunotherapy for stage Ⅱ and Ⅲ colon cancer with an autologous tumor cell vaccine: Easterm Cooperative Oncology Group Study E5283[J]. J Clin Oncol, 2000, 18(1): 148-157.
7Vermorken JB, Claessen AM, Van Tinteren H, et al. Active specific immunotherapy for stage Ⅱ and stage Ⅲ human colon cancer: a randomized trial[J]. Lancet, 1999, 353(9150): 345-350.
8Gandernack G, Gjertsen MK. Combination of GM-CSF with antitumour vaccine strategies[J]. Eur J Cancer, 1999, 35(Suppl 3): S33-S35.
9Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocytemacroghage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma[J]. Proc Natl Acad Sci USA, 1998, 95(22): 13141-13146.
10Zhang R, Minemura K, De Groot LJ, et al. Irnmunotherapy for medullary thyroid carcinoma by a replication-defective adenovirus transducing murine interleukin-2[J]. Endocrinology, 1998, 139(2): 601-608.
3Shan B E,Yoshida Y,Sugiura T et al.Stimulating activity of Chinese medicinal herbs on human lymphocytes in vitro[J].International J Immunopharmacology,1999;21(3):149-159.
4Banchereau J,Steinman R M.Dendritic cells and the control of immunity[J].Nature,1998;392(6673):245-252.
5Harada N,Kodama N,Nanba H.Relationship between dendritic cells and the D-fraction-induced Th-1 dominant response in BALB/c tumor-bearing mice[J].Cancer Lett,2003;192(2):181-187.
6Inoue A,Kodama N,Nanba H.Effect of maitake(Grifola frondosa) D-fraction on the control of the T lymph node Th1/Th2 proportion[J].Biol Pharm Bull,2002;25(4):536-540.
7Mailliard R B,Dallal R M,Son Y I et al.Dendritic cells promote T-cell survival or death depending upon their maturation state and presentation of antigen[J].Immunol Invest,2000;29(2):177-185.
8Kim G Y,Oh Y H,Park Y M.Acidic polysaccharide isolated from Phellinus induces nitric oxide-mediated tumoricidal activity of macrophages through protein tyrosine kinase and protein kinase C[J].Biochem Biophys Res Commun,2003;309(2):399-407.
9Matsuda H,Toguchida I,Ninomiya K et al.Effects of sesquiterpenes and amino acid-sesquiterpene conjugates from the roots of Saussurea lappa on inducible nitric oxide synthase and heat shock protein in lipopolysaccharide-activated macrophages[J].Bioorg Med Chem,2003;11(5):709-715.
10Currier N L,Miller S C.Natural killer cells from aging mice treated with extracts from Echinacea purpurea are quantitatively and functionally rejuvenated[J].Exp Gerontol,2000;35(5):627-639.
